By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Correlogic Systems this week said that it has fulfilled European Union regulatory requirements to CE Mark its OvaCheck test for epithelial ovarian cancer. The test is a multiplex assay that measures the relative ratios of eight proteins. The Germantwon, Md.-based firm said that it is currently in discussions with potential partners for distribution of OvaCheck in Europe.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.